Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Cancer Research

• Publication date

  2014-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-13-3017PMID 24634374PMCID PMC4070853
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.

  2013cited by this paper
• A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• A human memory T-cell subset with stem cell-like properties

  2011cited by this paper
• A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity.

  2011cited by this paper
• Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells

  2011cited by this paper
• Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses

  2010cited by this paper
• Systemic cytokine response in patients with community-acquired pneumonia

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

  2010cited by this paper
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009cited by this paper
• mTOR regulates memory CD8 T cell differentiation

  2009cited by this paper
• Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells.

  2009cited by this paper
• Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

  2008cited by this paper
• Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1

  2006cited by this paper
• Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays

  2006cited by this paper
• CD8+ T‐cell memory in tumor immunology and immunotherapy

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.

  2005cited by this paper
• Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

  2005cited by this paper
• Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo

  2004influential reference
• Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy

  2004cited by this paper
• Immunotherapy of established tumors using bone marrow transplantation with antigen gene–modified hematopoietic stem cells

  2003cited by this paper
• Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

  2003cited by this paper
• Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

  2003cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells

  2002cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.

  2000cited by this paper
• Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.

  1998cited by this paper
• Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

  1997influential reference
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Transfection of the CD8 gene enhances T-cell recognition

  1987cited by this paper

• Safe and Efficient CRISPR Genome Editing of Primary Human T Cells Using a Droplet-Based Cell Mechanoporation Platform.

  2026cites this paper
• SARDH in the 1-C metabolism sculpts the T-cell fate and serves as a potential cancer therapeutic target

  2025cites this paper
• Polymerised superparamagnetic antigen presenting cell lymphocyte capture for enriching tumour reactive T-cells and neoantigen identification

  2025cites this paper
• Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny

  2025cites this paper
• Engineering adoptive cell therapy for solid tumors

  2025cites this paper
• Neoantigen identification and TCR-T therapy development for solid tumors: current advances and future perspectives

  2025cites this paper
• Immuno-oncology approaches to overcome T cell exhaustion in melanoma.

  2025cites this paper
• Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies

  2025cites this paper
• Targeting the roots of myeloid malignancies with T cell receptors

  2025cites this paper
• Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies

  2025cites this paper
• Fatty acid in the tumor microenvironment: perspectives for immunotherapy.

  2025cites this paper
• RESET: A TCR-coupled antigen receptor with superior targeting sensitivity and reversible drug-regulated anti-tumor activity

  2025cites this paper
• A therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors

  2025cites this paper
• Tumor immunotherapy: past, present, and future

  2025cites this paper
• Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy

  2025cites this paper
• Prospect of chimeric antigen receptor T-cell therapy for cancer

  2025cites this paper
• Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models

  2024cites this paper
• Solid tumour cellular therapy — principles of toxicity management

  2024cites this paper
• Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy

  2024cites this paper
• Recent Advancements in Cell-Based Therapies in Melanoma

  2024cites this paper
• Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors.

  2024cites this paper
• Novel immunotherapeutic approaches in gastric cancer

  2024cites this paper
• Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review.

  2024cites this paper
• Artificial Antigen‐Presenting Cell Fabrication for Murine T Cell Expansion

  2024cites this paper
• Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy

  2024cites this paper
• Immunotherapy in melanoma: advances, pitfalls, and future perspectives

  2024cites this paper
• Two effective factors in cancer: Investigating the effect of ncRNAs in cancer and also the effect of nanotherapy in its treatment.

  2024cites this paper
• The role of dendritic cells in cancer immunity and therapeutic strategies.

  2024cites this paper
• CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes

  2024cites this paper
• Fatty acid metabolism of immune cells: a new target of tumour immunotherapy

  2024cites this paper
• Adoptive T cell therapy for solid tumors: current landscape and future challenges

  2024cites this paper
• Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities

  2024cites this paper
• Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A*02:01 complex.

  2024cites this paper
• CRISPR–Cas9 applications in T cells and adoptive T cell therapies

  2024cites this paper
• Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

  2023cites this paper
• TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

  2023cites this paper
• Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

  2023cites this paper
• Stocking the toolbox—Using preclinical models to understand the development and treatment of immune checkpoint inhibitor‐induced immune‐related adverse events

  2023cites this paper
• Adoptive T cells therapy in solid tumors: state-of-the art, current challenges, and upcoming improvements.

  2023cites this paper
• Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy

  2023cites this paper
• The molecular perspective on the development of melanoma and genome engineering of T-cells in targeting therapy.

  2023cites this paper
• Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4

  2023cites this paper
• The landscape of T cell antigens for cancer immunotherapy

  2023cites this paper
• Challenges and solutions for therapeutic TCR‐based agents

  2023cites this paper
• CD4 T cells and toxicity from immune checkpoint blockade

  2023cites this paper
• Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis

  2023cites this paper
• Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer

  2022cites this paper
• What’s next for cancer vaccines

  2022cites this paper
• Clinical and Translational Advances in Glioma Immunotherapy

  2022cites this paper
• A bead-based method for high-throughput mapping of the sequence- and force-dependence of T cell activation

  2022cites this paper
• TCR engineered T cells for solid tumor immunotherapy

  2022cites this paper
• Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis

  2022cites this paper
• Personalized cancer immunotherapy

  2022cites this paper
• Stem cell like memory T cells: A new paradigm in cancer immunotherapy.

  2022cites this paper
• Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation

  2022cites this paper
• Dendritic cell transfer for cancer immunotherapy.

  2022cites this paper
• MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial

  2022cites this paper
• A Brief Introduction to Current Cancer Gene Therapy.

  2022cites this paper
• Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma

  2022cites this paper
• Clinical Correlation of Function and TCR vβ Diversity of MAGE-C2–Specific CD8+ T Cell Response in Esophageal Cancer

  2022cites this paper
• Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

  2022cites this paper
• Fatty Acid Metabolism and Cancer Immunotherapy

  2022cites this paper
• Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects

  2022cites this paper
• Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

  2022cites this paper
• Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis

  2021cites this paper
• TCR gene-engineered cell therapy for solid tumors.

  2021cites this paper
• Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy

  2021cites this paper
• Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities

  2021cites this paper
• Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy

  2021cites this paper
• Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead

  2021cites this paper
• Advances in Cellular Immunotherapy in Hematologic Malignancies

  2021cites this paper
• Overview of Cellular Immunotherapies within Transfusion Medicine for the Treatment of Malignant Diseases

  2021cites this paper
• Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment.

  2021cites this paper
• Breast cancer immunotherapy: Current and novel approaches.

  2021cites this paper
• Cellular Therapy and Cytokine Treatments for Melanoma.

  2021cites this paper
• Structure-activity mapping of the peptide- and force-dependent landscape of T-cell activation

  2021cites this paper
• Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy

  2021cites this paper
• Nanomedicine-mediated ubiquitination inhibition boosts antitumor immune response via activation of dendritic cells

  2021cites this paper
• 1% of Bill Goddard

  2021cites this paper
• Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer

  2021cites this paper
• HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells

  2021cites this paper
• [T cell-based immunotherapies in solid tumors].

  2021cites this paper
• T cell receptor (TCR) signaling in health and disease

  2021cites this paper
• Cell Therapy: Types, Regulation, and Clinical Benefits

  2021influential citation
• Title: Characterization of the Genomic and Immunological Diversity of Malignant Brain Tumors

  2021cites this paper
• Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer

  2021cites this paper
• Engineered T-cell Receptor T Cells for Cancer Immunotherapy

  2021influential citation
• CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More

  2021cites this paper
• Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers

  2021cites this paper
• Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells

  2020cites this paper
• The Influence of Tumor Microenvironment on Immune Escape of Melanoma

  2020cites this paper
• Understanding Checkpoint Inhibitors in Cancer Therapy, Mechanisms of Action, Resistance and Future Challenges

  2020cites this paper
• TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

  2020influential citation
• Human immunology and immunotherapy: main achievements and challenges

  2020cites this paper
• CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead

  2020cites this paper
• Conventional T cell therapies pave the way for novel Treg therapeutics.

  2020cites this paper
• Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy.

  2020influential citation
• The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses

  2020cites this paper
• Current Immunotherapeutic Strategies in Cancer

  2020cites this paper
• Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma.

  2020cites this paper